Ovid Therapeutics Inc.

NASDAQ:OVID

Biotechnology

Healthcare
$2.26 -4.34%

-$0.11 today

Market cap
$426.53M
Beta
0.18
P/E (TTM)
-7.1
EPS (TTM)
-$0.33
52W Low $0.29High $3.11

Volume 2.16M

Average 3.07M

OVID Purchases of Investments

Cash used to buy marketable securities and other investments.

Ovid Therapeutics Inc.NASDAQ: OVID

Purchases of Investments · Q1 FY2026 · quarter ended Mar 2026

Purchases of investments dips below year-ago levels

Q1 FY2026 purchases of investments of $4.05M (cash outflow) fell 17.3% year over year, behind the +33.1% change in trailing-twelve-month purchases of investments. Sequentially, it fell 94.7% from the prior quarter. Over 3 fiscal years it compounded at -19.0% a year.

Context

  • Purchases of investments amounted to 1266.6% of revenue in FY2025, down 11674.4 pp from a year earlier.
  • Purchases of investments grew in size in 1 of the last 3 fiscal years.

What to watch

Whether quarterly growth recovers from -17.3% toward the trailing-twelve-month pace of +33.1%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
-$4.05M-94.7% QoQ
Last fiscal yearDec 2025
-$91.85M+25.4% YoY
LTMMar 2026
-$91.01M+33.1% YoY
Purchases of Investments past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-17.3%——
1 year+25.4%——
3-year CAGR-19.0%——
5-year CAGR——
10-year CAGR——

Purchases of Investments history

USD · from the cash flow

Latest · FY2025
(91.85M) USD
Year-over-year change
-25.4%

Purchases of Investments vs competitors

How OVID compares with its peers on the latest reported figures

  • OVID's LTM Mar 2026 purchases of investments of $91.01M is the 8th largest of the 11 companies compared; the peer median is $181.16M.
  • Its year-over-year change of +33.1% is the 3rd highest of 8, against a peer median of +0.4%.
  • Purchases of investments amounts to 1277.8% of revenue for OVID, versus a peer median of 47.4%.
OVID Competitors Peer median
Purchases of Investments for OVID and competitors
Company Period LTM YoY 3-year CAGR% of revenue
RAREUltragenyx Pharmaceutical Inc.LTM Mar 2026$317M -18.0%-32.9%47.4%
STOKStoke Therapeutics, Inc.LTM Mar 2026$313.56M +68.3%+17.0%977.4%
NGNENeurogene Inc.LTM Mar 2026$261.83M +16.9%——
LXEOLexeo Therapeutics, Inc. Common StockLTM Mar 2026$195.4M +108.8%——
RCKTRocket Pharmaceuticals, Inc.LTM Mar 2026$185.33M -42.4%-9.8%—
ABEOAbeona Therapeutics Inc.LTM Mar 2026$176.99M +0.4%+38.2%1217.3%
VYGRVoyager Therapeutics, Inc.LTM Mar 2026$100.45M -70.3%+34.7%275.2%
OVIDOvid Therapeutics Inc.LTM Mar 2026$91.01M +33.1%-19.0%1277.8%
TSHATaysha Gene Therapies, Inc.LTM Jun 2026$0 ——0.0%
MGTXMeiraGTx Holdings plcLTM Mar 2026$0 ——0.0%
WVEWave Life Sciences Ltd.LTM Mar 2026$0 ——0.0%
Peer median (excluding OVID) $181.16M+0.4%+17.0%47.4%

Competitors are the stored peer set for OVID. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income119.84M(54.17M)(52.34M)(26.43M)(17.41M)
Depreciation & Amortization237K1.38M1.6M613K273K
Deferred Income Tax00000
Stock-Based Compensation06.56M7.29M6.28M4.81M
Change in Working Capital(16.81M)(8.23M)2.39M(150K)(4.1M)
Accounts Receivables141.76K0000
Inventory00000
Accounts Payables1.7M(5.17M)1.75M(512K)(1.23M)
Other Working Capital(18.66M)(3.06M)635.51K362K(2.87M)
Other Non-Cash Items15.35M(764.94K)(4.71M)(36.26M)(21.9M)
Operating Cash Flow118.61M(55.23M)(45.78M)(55.96M)(38.33M)
Capital Expenditures(189.41K)(1.42M)(137.46K)(71K)0
Acquisitions (Net)(1.63M)(2.5M)(10M)00
Purchases of Investments(1.63M)(172.96M)(112.44M)(73.25M)(91.85M)
Sales of Investments090M120M128M42M
Other Investing Activities(5.4K)(1M)(97.15K)(89K)0
Investing Cash Flow(1.82M)(87.88M)(2.58M)54.59M(49.85M)
Debt Repayment0030M00
Common Stock Issued925.4K180.66K535.2K622K75.21M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities(21.31K)0000
Financing Cash Flow904.08K180.66K30.54M622K75.21M
Effect of Forex Changes(1.93M)000(167K)
Net Change in Cash115.76M(142.93M)(17.83M)(740K)(13.15M)
Free Cash Flow118.42M(56.65M)(45.92M)(56.03M)(38.33M)

Ovid Therapeutics Inc.

NASDAQ:OVID

Intrinsic Alpha fair value

Locked

Current Price

$2.26

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.